An update on the phase 3 MDS-005 trial

At the 20th Congress of the European Hematology Association (EHA), Valeria Santini, MD, of the University of Florence, Florence, Italy, discusses the phase 3 MDS-005 trial, which evaluated the impact of baseline erythropoietin levels on red blood cell (RBC)-transfusion independence in lenalidomide-treated patients with low or intermediate-1-risk myelodysplastic syndromes without deletion 5q.

Share this video  
11th June 2015